priors.science/reviews/rheumatoid-arthritis-targeted-therapy

Rheumatoid Arthritis Targeted Therapy

The current evidence on 6 claims, ordered from most established to most contested. Each score is the panel’s evidence certainty — how firmly the literature supports the claim as stated.

6claims tracked
84primary papers reviewed
9 Aug 2026latest evidence review
Weeklyre-scored against new papers
0 Established · 5 Likely · 0 Uncertain · 1 Doubtful  |  four-reviewer panel · PICO Framework
ClaimStandingEvidence certaintyCorpus
TNF inhibitors improve response and slow radiographic progression in methotrexate-inadequate rheumatoid arthritisTNF BiologicsLikely83%19
JAK inhibitors match biologic disease-modifying antirheumatic drugs for remission in rheumatoid arthritis, given orallyJAK InhibitorsLikely79%9
Treat-to-target strategy improves outcomes versus routine care in rheumatoid arthritisT2T StrategyLikely79%14
Interleukin-6 receptor inhibitors achieve responses in rheumatoid arthritis, tocilizumab superior to adalimumabNon TNF BiologicsLikely76%18
Abatacept and rituximab match TNF inhibitors in rheumatoid arthritisNon TNF BiologicsLikely73%17
Tofacitinib cardiovascular and malignancy safety signal reflects a JAK class effectJAK InhibitorsDoubtful45%10
Track Rheumatoid Arthritis Targeted Therapy.
These claims are re-scored against new papers every week. Track this topic for the full review, including each claim’s challenge and the papers behind it.
Track this topic →
Standing — what the evidence certainty means
Established≥ 85%Strong, consistent evidence. Unlikely to change.
Likely70–84%Well supported, with some gaps or indirect evidence.
Uncertain50–69%Mixed or limited evidence. Genuinely open.
Doubtful30–49%Little support; the weight of evidence leans against it.
Refuted< 30%The evidence contradicts it — confidently false as stated.